XML 29 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1
Derivative Warrant Liabilities (Tables)
 3 Months Ended
Mar. 31, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Outstanding Warrants Liabilities

The remaining outstanding warrants and terms as of March 31, 2018 and December 31, 2017 is as follows:

 

Issuance date   Outstanding as of December 31, 2017     Outstanding as of March 31,
2018		     Exercise
Price		     Exercisable as of March 31,
2018		     Exercisable Through
                             
Series A (2013)     57,814       57,814     $ 194.40       57,814     October 2018
Series A (2013)     2,718       2,718     $ 183.60       2,718     April 2023
Series A (2015)     10,139       10,139     $ 91.80       10,139     April 2020
Series A (2016) (a)     9,279       -     $ -       -     March 2018
Series B (2016) (a)     41,116       41,116     $ 2.70       41,116     March 2022

 

 

  a) These warrants contain a full ratchet anti-dilution price protection so that, in most situations upon the issuance of any common stock or securities convertible into common stock at a price below the then-existing exercise price of the outstanding warrants, the warrant exercise price will be reset to the lower common stock sales price. As such anti-dilution price protection does not meet the specific conditions for equity classification, the Company is required to classify the fair value of these warrants as a liability, with changes in fair value to be recorded as income (loss) due to change in fair value of warrant liability. The estimated fair value of our warrant liability at March 31, 2018 and December 31, 2017, was approximately $15 and $28, respectively.
Schedule of Valuation of Derivative Warrant Liabilities

The following table summarizes the observable inputs used in the valuation of the derivative warrant liabilities as of March 31, 2018 and December 31, 2017:

 

    Series A
(2011)		     Series A (2013)     Series A (2013)     Series A (2015)     Series A
(2016)		     Series B
(2016)		     Total  
Balances at December 31, 2017   $   -     $ -     $ -     $ -       $ (*)     $ 28     $ 28  
Exercised     -       -       -       -       -       -       -  
Cancelled     -       -       -       -       -       -       -  
Changes in fair value     -       -       -       -       (*)       (13 )     (13 )
Balances at March 31, 2018   $ -     $ -     $ -     $ -     $ -     $ 15     $ 15  

 

 

(*) Less than 1
Schedule of Fair Value Assumption

The following table summarizes the observable inputs used in the valuation of the derivative warrant liabilities as of March 31, 2018 and December 31, 2017:

 

    As of March 31, 2018     As of December 31, 2017  
    Series A (2016)     Series B (2016)     Series A (2016)     Series B (2016)  
Share price     —     $ 0.69     $ 1.02     $ 1.02  
Exercise price     —     $ 2.70     $ 2.70     $ 2.70  
Expected volatility     —       109 %     60 %     119 %
Risk-free interest     —       2.39 %     1.24 %     1.89 %
Dividend yield     —       —       —       —  
Expected life of up to (years)     —       4.00       0.25       4.25  
Schedule of Liabilities Measured on a Recurring Basis

Activity in such liabilities measured on a recurring basis is as follows:

 

    Derivative Warrant Liabilities  
As of December 31, 2017   $ 28  
Revaluation of warrants     (13 )
As of March 31, 2018   $ 15  

 

    Derivative Warrant Liabilities  
As of December 31, 2016   $ 313  
Revaluation of warrants     (285 )
Exercise warrants     (* )
As of December 31, 2017   $ 28  

 

 

(*) Less than 1